Back to Search
Start Over
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
- Source :
-
British Journal of Dermatology . Feb2024, Vol. 190 Issue 2, p289-291. 3p. - Publication Year :
- 2024
-
Abstract
- The article discusses the results of two phase III clinical trials, ADvocate1 and ADvocate2, which examined the efficacy and safety of lebrikizumab monotherapy in patients with moderate-to-severe atopic dermatitis (AD). The trials found that lebrikizumab significantly improved patient-reported itch and reduced sleep loss due to itch. The improvements in itch and sleep loss were observed as early as the first few days of treatment and were consistent with previous studies on lebrikizumab. The study was funded by Dermira, a subsidiary of Eli Lilly and Company, and medical writing assistance was provided by ProScribe–Envision Pharma Group. [Extracted from the article]
- Subjects :
- *CLINICAL trials
*ITCHING
*ATOPIC dermatitis
*SLEEP
Subjects
Details
- Language :
- English
- ISSN :
- 00070963
- Volume :
- 190
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- British Journal of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 175045681
- Full Text :
- https://doi.org/10.1093/bjd/ljad435